Literature DB >> 19200051

The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells.

V Badireenath Konkimalla1, James A McCubrey, Thomas Efferth.   

Abstract

Epidermal growth factor (EGF) and its receptor (EGFR) as well as the EGFR-coupled Ras>Raf>MEK>ERK pathway are known to affect the survival of cancer cells upon chemotherapeutic treatment. In the present investigation, we analyzed the role of EGFR signaling pathways for the activity of artesunate towards cancer cells. The microarray-based mRNA expression of genes involved in EGFR signaling pathway was correlated with the 50% inhibition concentrations (IC<inf>50</<inf>) of 55 tumor cell lines for artesunate. The log10IC<inf>50</<inf> values were in a range of -6.609 to -4.0M. Candidate genes identified by this approach were then experimentally validated by transfecting cell lines with corresponding cDNA vectors and treating them with artesunate. Indeed, we observed that the Ras>Raf>MEK>ERK pathway is an important signaling route for the response of tumor cells to artesunate. As exemplarily shown for artesunate, the application of such a combined approach to identify signal transduction pathways involved in the response of tumor cells to cytotoxic compounds might foster the development of novel molecular targeted therapies for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200051     DOI: 10.2174/156800909787314020

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

Review 1.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

2.  Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production.

Authors:  Anne Hamacher-Brady; Henning A Stein; Simon Turschner; Ina Toegel; Rodrigo Mora; Nina Jennewein; Thomas Efferth; Roland Eils; Nathan R Brady
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

3.  Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models.

Authors:  Ying-Jie Chen; Jia-Ying Wu; Yu-Yi Deng; Ying Wu; Xiao-Qi Wang; Amy Sze-Man Li; Lut Yi Wong; Xiu-Qiong Fu; Zhi-Ling Yu; Chun Liang
Journal:  J Ginseng Res       Date:  2021-07-14       Impact factor: 5.735

4.  In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.

Authors:  Hongyi Cai; Arun Kapoor; Ran He; Rajkumar Venkatadri; Michael Forman; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

5.  A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.

Authors:  Sanjeev Krishna; Senthil Ganapathi; Irina Chis Ster; Mohamed E M Saeed; Matt Cowan; Caroline Finlayson; Hajnalka Kovacsevics; Herwig Jansen; Peter G Kremsner; Thomas Efferth; Devinder Kumar
Journal:  EBioMedicine       Date:  2014-11-15       Impact factor: 8.143

6.  Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua.

Authors:  Elmar Breuer; Thomas Efferth
Journal:  Nat Prod Bioprospect       Date:  2014-04-12

7.  Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.

Authors:  Da Eun Jeong; Hye Jin Jin Song; Sharon Lim; Se Jeong Jeong Lee; Joung Eun Lim; Do-Hyun Nam; Kyeung Min Joo; Byong Chang Jeong; Seong Soo Jeon; Han Yong Choi; Hye Won Lee
Journal:  Oncotarget       Date:  2015-10-20

8.  Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines.

Authors:  Serkan Sertel; Tolga Eichhorn; Christian H Simon; Peter K Plinkert; Steven W Johnson; Thomas Efferth
Journal:  Molecules       Date:  2010-04-22       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.